CHMP recommends pirtobrutinib for relapsed or refractory CLL
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of.
Is CAR-T feasible in elderly patients with B-cell lymphoma?
Octogenarians with B-cell lymphoma may be considered for chimeric antigen receptor (CAR) T-cell treatment, according to a study led by.
Dr. Lipof discusses Myeloma Action Month
In this video interview, Jodi Lipof, MD, explains why Myeloma Awareness Month matters more than ever.
1st SOHO Spain debuts in Madrid, bringing together global hematologists
Dr. Garcia-Manero writes about how the first SOHO Spain brought together 400 top international hematologists for its inaugural meeting in.
No benefit to adding pevonedistat to SOC for patients with newly diagnosed AML
The addition of pevonedistat to azacitidine plus venetoclax failed to significantly improve response rates.
Potential risk of lymphoma in individuals with large tattoos
Individuals with tattoos, particularly larger ones, may have an increased risk of lymphoma and skin cancer, according to a recent.
Do we need to take a closer look at the use of MRD to determine
A Viewpoints article published in The Lancet Haematology, calls for further research into the use of measurable residual disease (MRD).
ANVISA approves ropeginterferon alfa-2b in adults with polycythemia vera
The Brazilian Health Regulatory Agency (ANVISA) has approved ropeginterferon alfa-2b (BESREMi) for the treatment of adult patients with polycythemia vera.
Liso-cel favorable benefit over mosunetuzumab in 3rd-line R/R follicular lymphoma
Lisocabtagene maraleucel (liso-cel) was found to offer a favorable benefit–risk profile relative to mosunetuzumab as a third-line or later treatment for.
SOHO launches new fundraising initiative
SOHO is launching a special fundraising initiative now through its Thirteenth Annual Meeting in Houston, Texas, taking place between September.
EC expands use of liso-cel CAR T-cell therapy for relapsed or refractory follicular lymphoma
The European Commission (EC) has granted approval to lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for.
China NMPA approves IND for KPG-818 in relapsed or refractory MM
The Center for Drug Evaluation of the China National Medical Products Administration (NMPA) approved the IND application for KPG-818.
Nanobody-based CD7 CAR-T induces responses in patients with AML in early-phase study
A phase 1 study found that “naturally selected” CD7 chimeric antigen receptor T-cell (NS7CAR-T) therapy was well-tolerated and induced complete.
Top Categories
POPULAR NEWS
NCI’s myeloMATCH pushes the envelope in myeloid leukemia care
January 3, 2025
Asciminib benefit-risk profile bests other TKIs in CML
December 10, 2024
Pathways & Perspectives with Pia Raanani, MD
January 3, 2025
Meetings
Editorial Board
Join Us Today and Become a Part of the SOHO Community
- Instant connections to our SOHO Communityof nearly 9,000 members
- Access to a comprehensive Resource Centerthat includes slides, publications, abstracts, videos & more
- Connection to our SOHO DocMatter Communityfor hematologic oncology discussions and education
- Free online access to our official journal, ‘Clinical Lymphoma Myeloma and Leukemia
- Free online and print subscription (US members) to our news publication,'SOHO Insider'
- Significant member-only discounts on meetings and events
- Early member-only registration and housing opportunities
- ... and much more!
SOHO Career Center
- Create a job seeker profile
- Perform intuitive searches for new jobs
- Auto-fill your resume through uploaded files
- Apply to new jobs through a streamlined workflow
- Receive email alerts when new relevant jobs are posted
To access the SOHO Career Center click the following link.
